• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Pyxis Oncology Inc.

    1/26/24 4:36:06 PM ET
    $PYXS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PYXS alert in real time by email
    SC 13G 1 tm244282d1_sc13g.htm SC 13G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

    SCHEDULE 13G

    (Amendment No. __)

     

    UNDER THE SECURITIES EXCHANGE ACT OF 19341

     

    PYXIS ONCOLOGY, INC.

    (Name of Issuer)

     

    Common Stock, par value $0.001 per share

    (Title of Class of Securities)

     

    747324 101

    (CUSIP Number)

     

    January 26, 2024

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨ Rule 13d-1(b)

     

    x Rule 13d-1(c)

     

    ¨ Rule 13d-1(d)

     

     

     

    1 The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

    CUSIP NO. 747324 10113GPage 2 of 10

     

    1.

    NAMES OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Ridgeback Capital Investments L.P.               66-0677421

     

    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP** (a) ¨
    (b) ¨ 
    3.

    SEC USE ONLY

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH

    5.

    SOLE VOTING POWER

     

    -0-

    6.

    SHARED VOTING POWER

     

    4,345,228

    7.

    SOLE DISPOSITIVE POWER

     

    -0-

    8.

    SHARED DISPOSITIVE POWER

     

    4,345,228

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    4,345,228

    10.

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW 9 EXCLUDES CERTAIN SHARES**

     

    ¨
    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    9.8%

    12.

    TYPE OF REPORTING PERSON**

     

    OO

     

    ** SEE INSTRUCTIONS BEFORE FILLING OUT

     

    CUSIP NO. 747324 10113GPage 3 of 10

     

    1.

    NAMES OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Ridgeback Capital Investments LLC              72-1614961

     

    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP** (a) ¨
    (b) ¨
    3.

    SEC USE ONLY

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH

    5.

    SOLE VOTING POWER

     

    -0-

    6.

    SHARED VOTING POWER

     

    4,345,228

    7.

    SOLE DISPOSITIVE POWER

     

    -0-

    8.

    SHARED DISPOSITIVE POWER

     

    4,345,228

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    4,345,228

    10.

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW 9 EXCLUDES CERTAIN SHARES**

     

    ¨
    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    9.8%

    12.

    TYPE OF REPORTING PERSON**

     

    OO

     

    ** SEE INSTRUCTIONS BEFORE FILLING OUT

     

    CUSIP NO. 747324 10113GPage 4 of 10

     

    1.

    NAMES OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Ridgeback Capital Management LLC              42-1684320

     

    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP** (a) ¨
    (b) ¨
    3.

    SEC USE ONLY

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH

    5.

    SOLE VOTING POWER

     

    -0-

    6.

    SHARED VOTING POWER

     

    4,345,228

    7.

    SOLE DISPOSITIVE POWER

     

    -0-

    8.

    SHARED DISPOSITIVE POWER

     

    4,345,228

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    4,345,228

    10.

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW 9 EXCLUDES CERTAIN SHARES**

     

    ¨
    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    9.8%

    12.

    TYPE OF REPORTING PERSON**

     

    OO

     

    ** SEE INSTRUCTIONS BEFORE FILLING OUT

     

    CUSIP NO. 747324 10113GPage 5 of 10

     

    Item 1(a). Name of Issuer.

     

    Pyxis Oncology, Inc. (the “Company”).

     

    Item 1(b). Address of Issuer’s Principal Executive Offices.

     

    The Company’s principal executive offices are located at 321 Harrison Avenue, Boston, MA 02118.

     

    Items 2(a). Name of Person Filing.

     

    This statement is filed on behalf of the following persons with respect to shares of common stock of the Company acquired by them (the “Shares”):

     

    (i)Ridgeback Capital Investments L.P., Delaware limited partnership (“RCILP”), with respect to Shares beneficially owned by it;
      
    (ii)Ridgeback Capital Investments LLC, a Delaware limited liability company (“RCI”), with respect to Shares beneficially owned by it; and
      
    (iii)Ridgeback Capital Management LLC, a Delaware limited liability company (“RCM”), with respect to Shares beneficially owned by it.

     

    The foregoing persons are hereinafter referred to collectively as the “Reporting Persons.” Any disclosures herein with respect to persons other than the Reporting Persons are made on information and belief after making inquiry to the appropriate party.

     

    Item 2(b).Address of Principal Business Office or, if None, Residence.

     

    The address of the principal business office of each of the Reporting Persons is 30 Star Island Drive, Miami, FL, 33139.

     

    Item 2(c).Citizenship.

     

    RCILP is a Delaware limited partnership. RCI is a Delaware limited liability company. RCM is a Delaware limited liability company.

     

    Item 2(d).Title of Class of Securities.

     

    Common stock, $0.001 par value per share.

     

    CUSIP NO. 747324 10113GPage 6 of 10

     

    Item 2(e).CUSIP Number.

     

    747324 101

    Item 3.

     

    If this statement is filed pursuant to Rules 13d-1(b) or 13d- 2(b) or (c), check whether the person filing is a:

     

    (a) ¨  Broker or dealer registered under Section 15 of the Act,
    (b) ¨  Bank as defined in Section 3(a)(6) of the Act,
    (c) ¨  Insurance Company as defined in Section 3(a)(19) of the Act,
    (d) ¨  Investment Company registered under Section 8 of the Investment Company Act of 1940,
    (e) ¨  Investment Adviser in accordance with Rule 13d-1 (b)(1)(ii)(E),
    (f) ¨  Employee Benefit Plan or Endowment Fund in accordance with 13d-1 (b)(1)(ii)(F),
    (g) ¨  Parent Holding Company or control person in accordance with Rule 13d-1 (b)(1)(ii)(G),
    (h) ¨  Savings Association as defined in Section 3(b) of the Federal Deposit Insurance Act,
    (i) ¨  Church Plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940,
    (j) ¨  A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J),
    (k) ¨ 

    Group, in accordance with Rule 13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please specify the type of institution: _______________.

     

    Item 4.Ownership.

     

    The percentages used herein are calculated based upon 44,323,046 shares outstanding as of November 6, 2023 as reported in the Company’s Quarterly Report on Form 10-Q filed with the SEC on November 7, 2023. As of the close of business on January 26, 2024, the Reporting Persons beneficially owned shares of the Company’s common stock in the amounts and percentages listed below:

     

    A. Ridgeback Capital Investments L.P.
    (a) Amount beneficially owned:  4,345,228

     

    CUSIP NO. 747324 10113GPage 7 of 10

     

    (b) Percent of class: 9.8%
    (c) (i) Sole power to vote or direct the vote: -0-
      (ii) Shared power to vote or direct the vote:  4,345,228
      (iii) Sole power to dispose or direct the disposition:  -0-
      (iv) Shared power to dispose or direct the disposition:  4,345,228
         
    B. Ridgeback Capital Investments LLC
    (a) Amount beneficially owned:  4,345,228
    (b) Percent of class: 9.8%
    (c) (i) Sole power to vote or direct the vote: -0-
      (ii) Shared power to vote or direct the vote:  4,345,228
      (iii) Sole power to dispose or direct the disposition:  -0-
      (iv) Shared power to dispose or direct the disposition:  4,345,228
       
    C. Ridgeback Capital Management LP
    (a) Amount beneficially owned:  4,345,228
    (b) Percent of class: 9.8%
    (c) (i) Sole power to vote or direct the vote: -0-
      (ii) Shared power to vote or direct the vote:  4,345,228
      (iii) Sole power to dispose or direct the disposition:  -0-
      (iv) Shared power to dispose or direct the disposition:  4,345,228

     

    RCM and RCI do not own any Shares directly. RCI is the general partner of RCILP. Pursuant to an investment management agreement, RCM maintains investment and voting power with respect to the securities held or controlled by RCI. Wayne Holman, an individual, controls RCM. By reason of the provisions of Rule 13d-3 of the Securities Exchange Act of 1934, as amended, RCM and RCI may be deemed to own beneficially all of the Shares (constituting approximately 9.8% of the shares outstanding). Each of RCM and RCI disclaim beneficial ownership of any of the securities covered by this statement, except to the extent of any pecuniary interest therein.

     

    CUSIP NO. 747324 10113GPage 8 of 10

     

    Item 5.Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following.   ¨

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

     

    To the knowledge of the Reporting Persons, no other person has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, a number of the Shares which represents more than five percent of the number of outstanding shares of the Shares.

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

     

    Not Applicable.

     

    Item 8.Identification and Classification of Members of the Group.

     

    Not Applicable.

     

    Item 9.Notice of Dissolution of Group.

     

    Not Applicable.

     

    Item 10.Certifications.

     

    Each of the Reporting Persons hereby makes the following certification:

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

    CUSIP NO. 747324 10113GPage 9 of 10

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    DATED: January 26, 2024

     

        Ridgeback Capital Investments L.P.
         
        By: Ridgeback Capital Investments LLC,
        Its General Partner
         
      By: /s/ Nicole Venezia
        Name: Nicole Venezia
        Title: General Counsel
         
        Ridgeback Capital Investments LLC
         
      By: /s/ Nicole Venezia
        Name: Nicole Venezia
        Title: General Counsel
         
        Ridgeback Capital Management LLC
         
      By: /s/ Nicole Venezia
        Name: Nicole Venezia
        Title: General Counsel

     

    CUSIP NO. 747324 10113GPage 10 of 10

     

    EXHIBIT INDEX

     

    Exhibit Number Exhibit Description
    99.1 Joint Filing Agreement

     

     

     

    Get the next $PYXS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PYXS

    DatePrice TargetRatingAnalyst
    11/21/2024Outperform → Mkt Perform
    William Blair
    11/8/2024$13.00Overweight
    Stephens
    8/8/2024$10.00Buy
    Stifel
    5/7/2024$10.00Buy
    Jefferies
    2/9/2024$8.00Buy
    BTIG Research
    1/23/2024$12.00Outperform
    Leerink Partners
    9/5/2023$7.00Outperform
    RBC Capital Mkts
    11/2/2021$16.00Neutral
    B of A Securities
    More analyst ratings

    $PYXS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Pyxis Oncology Reports First Quarter 2025 Financial Results and Provides Business Update

      - Announced robust preclinical data supporting the unique three-pronged mechanism of action of micvotabart pelidotin (MICVO, formerly PYX-201), driving anti-tumor activity via direct tumor killing, bystander effect and immunogenic cell death - On track to report preliminary data from Phase 1 monotherapy expansion cohorts of MICVO for 2L/3L R/M HNSCC patients who have received prior platinum-based chemotherapy and prior PD-(L)1 inhibitor therapy in second half of 2025, and 2L/3L R/M HNSCC patients who have received prior EGFRi and PD-1 inhibitor therapy in first half of 2026 - On track to report preliminary data from Phase 1 trial of MICVO in combination with pembrolizumab targeting mul

      5/15/25 7:00:00 AM ET
      $PYXS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pyxis Oncology to Participate in Two Upcoming Investor Conferences

      BOSTON, May 14, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (NASDAQ:PYXS), a clinical-stage company developing next-generation ADC therapeutics for difficult-to-treat cancers, today announced that Lara S. Sullivan, M.D., President, Chief Executive Officer and Chief Medical Officer, will participate in fireside chats and be available for one-on-one meetings with investors at the following two upcoming investor conferences. 2025 RBC Capital Markets Global Healthcare Conference in New York, NY on Wednesday, May 21 at 2:05 p.m. ETJefferies Global Healthcare Conference in New York, NY on Thursday, June 5 at 4:55 p.m. ET A live webcast and replay of the fireside chats will be available on th

      5/14/25 7:30:00 AM ET
      $PYXS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pyxis Oncology Presents Promising Preclinical Results Providing Proof of Mechanism of Micvotabart Pelidotin, the First-in-Concept Extracellular-Targeting ADC

      Gene signatures associated with increased efficacy of micvotabart pelidotin (MICVO) due to greater linker cleavage were identified based on differential gene expression analysis of PDX responders/non-responders Mouse analog of MICVO in a syngeneic model indicated strong activity of the cytotoxic Auristatin0101 payload and potential for MICVO monotherapy to drive immunogenic cell death, a key hypothesis for MICVO's mechanism Combination of a mouse analog of MICVO and anti-PD-1 therapy in a syngeneic model resulted in enhanced tumor clearance and longer immunological memory compared to either treatment alone Totality of pre-clinical data presented at AACR 2025 strongly support MICVO's uniqu

      4/25/25 1:17:47 PM ET
      $PYXS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PYXS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CFO & COO Connealy Pamela Ann bought $174,364 worth of shares (88,850 units at $1.96) (SEC Form 4)

      4 - Pyxis Oncology, Inc. (0001782223) (Issuer)

      11/27/24 5:09:59 PM ET
      $PYXS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Connealy Pamela Ann bought $14,960 worth of shares (8,000 units at $1.87), increasing direct ownership by 0.99% to 818,532 units (SEC Form 4)

      4 - Pyxis Oncology, Inc. (0001782223) (Issuer)

      9/28/23 4:32:03 PM ET
      $PYXS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wadhane Jitendra bought $4,675 worth of shares (2,500 units at $1.87), increasing direct ownership by 1% to 226,937 units (SEC Form 4)

      4 - Pyxis Oncology, Inc. (0001782223) (Issuer)

      9/27/23 6:37:45 PM ET
      $PYXS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PYXS
    SEC Filings

    See more
    • SEC Form 10-Q filed by Pyxis Oncology Inc.

      10-Q - Pyxis Oncology, Inc. (0001782223) (Filer)

      5/15/25 7:41:51 AM ET
      $PYXS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pyxis Oncology Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Pyxis Oncology, Inc. (0001782223) (Filer)

      5/15/25 7:35:33 AM ET
      $PYXS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Pyxis Oncology Inc.

      SCHEDULE 13G/A - Pyxis Oncology, Inc. (0001782223) (Subject)

      5/6/25 4:17:33 PM ET
      $PYXS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PYXS
    Financials

    Live finance-specific insights

    See more
    • Pyxis Oncology Provides Corporate Update and Reports Financial Results for Third Quarter 2024

      - Preliminary data from the first-in-patient Phase 1 dose escalation trial of PYX-201 to be announced at upcoming virtual and in-person event in New York City on Wednesday, November 20, 2024, at 4:30 p.m. ET - Preliminary data from the Phase 1 trial of PYX-106 is expected to be reported by year-end 2024 - Expected cash runway into 2H 2026 BOSTON, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (NASDAQ:PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, today reported financial results for the third quarter ended September 30, 2024, and provided a corporate update. The Company ended the third quarter of 20

      11/12/24 7:30:00 AM ET
      $PYXS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pyxis Oncology Provides Corporate Update and Reports Financial Results for Second Quarter 2024

      - Preliminary data from the Phase 1 trial of PYX-201 remains on track to be announced in the fall of 2024 - Preliminary data from the Phase 1 trial of PYX-106 is expected to be reported by year-end 2024 - Expected cash runway into 2H 2026 BOSTON, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (NASDAQ:PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, today reported financial results for the second quarter ended June 30, 2024, and provided a corporate update. The Company ended the second quarter of 2024 with $157.2 million in cash, cash equivalents, restricted cash and short-term investments, which is expected

      8/14/24 4:05:00 PM ET
      $PYXS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pyxis Oncology Provides Corporate Update and Reports Financial Results for First Quarter 2024

      PYX-201 Phase 1 trial clinical readout on track for fall of 2024 Executive Leadership Team expanded with the appointment of Stephen Worsley as Senior Vice President, Chief Business Officer PYX-106 Phase 1 trial clinical readout on track for 2H 2024 Expected cash runway into 2H 2026 BOSTON, May 14, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (NASDAQ:PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, today reported financial results for the first quarter ended March 31, 2024, and provided a corporate update. PYX-201, a first-in-concept tumor stroma targeting antibody-drug conjugate (ADC) against the stromal Extradom

      5/14/24 7:30:00 AM ET
      $PYXS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PYXS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by President ,CEO & CMO Sullivan Lara

      4 - Pyxis Oncology, Inc. (0001782223) (Issuer)

      4/2/25 9:06:50 AM ET
      $PYXS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Metzger Michael A

      4 - Pyxis Oncology, Inc. (0001782223) (Issuer)

      4/2/25 9:05:43 AM ET
      $PYXS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by SVP, Chief Accounting Officer Wadhane Jitendra

      4 - Pyxis Oncology, Inc. (0001782223) (Issuer)

      4/2/25 9:04:17 AM ET
      $PYXS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PYXS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Pyxis Oncology downgraded by William Blair

      William Blair downgraded Pyxis Oncology from Outperform to Mkt Perform

      11/21/24 7:55:42 AM ET
      $PYXS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Stephens initiated coverage on Pyxis Oncology with a new price target

      Stephens initiated coverage of Pyxis Oncology with a rating of Overweight and set a new price target of $13.00

      11/8/24 8:24:38 AM ET
      $PYXS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Stifel initiated coverage on Pyxis Oncology with a new price target

      Stifel initiated coverage of Pyxis Oncology with a rating of Buy and set a new price target of $10.00

      8/8/24 6:48:55 AM ET
      $PYXS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PYXS
    Leadership Updates

    Live Leadership Updates

    See more
    • Pyxis Oncology Expands Board of Directors with Appointment of Michael A. Metzger

      BOSTON, June 10, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: "PYXS"), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, today announced the appointment of Michael A. Metzger to its Board of Directors, effective June 10, 2024. Mr. Metzger has over 25 years of experience in the biopharmaceutical sector, currently serving as Chief Executive Officer and as a member of the Board of Directors of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) since 2015. "We are delighted to have Michael, a proven leader in our industry with a robust track record of success, join the board," said Lara S. Sullivan, M.D., President and Chief Ex

      6/10/24 7:30:00 AM ET
      $PYXS
      $SNDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pyxis Oncology Expands Board of Directors with Appointment of Santhosh Palani, Ph.D., CFA

      BOSTON, March 13, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: "PYXS"), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, today announced the appointment of Santhosh Palani, Ph.D., CFA, to its board of directors, effective March 12, 2024. "We are thrilled to have Santhosh join the Pyxis Oncology board. Santhosh brings a wealth of business, investment, strategic, and board experience to our team," said Lara S. Sullivan, M.D., President and Chief Executive Officer of Pyxis Oncology. "Santhosh's guidance, drawing from his experience working across the biopharma industry, will be invaluable as we continue clinical devel

      3/13/24 8:00:00 AM ET
      $PYXS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • 1910 Genetics Appoints Dr. Shaan C. Gandhi as Independent Board Director

      Dr. Gandhi is VP and Head of Strategic Partnerships for Pfizer Ignite and will bring clinical, strategic and financial leadership to biotech's board 1910 Genetics, the only biotech advancing small and large molecule drug discovery with an automated, multimodal AI platform, today announced the appointment of Shaan C. Gandhi, MD, DPhil, to its board of directors. Gandhi joins as an independent board director and will provide a critical clinical perspective alongside his extensive background in biotechnology investing and strategic collaboration at a time when 1910 Genetics continues to build pharmaceutical and technology partnerships and advance its own pipeline of AI-derived therapeutics.

      12/19/23 9:00:00 AM ET
      $PYXS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PYXS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Pyxis Oncology Inc.

      SC 13G/A - Pyxis Oncology, Inc. (0001782223) (Subject)

      11/12/24 11:53:51 AM ET
      $PYXS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Pyxis Oncology Inc.

      SC 13G/A - Pyxis Oncology, Inc. (0001782223) (Subject)

      11/6/24 4:36:24 PM ET
      $PYXS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Pyxis Oncology Inc. (Amendment)

      SC 13D/A - Pyxis Oncology, Inc. (0001782223) (Subject)

      4/3/24 5:10:59 PM ET
      $PYXS
      Biotechnology: Pharmaceutical Preparations
      Health Care